PAVM

PAVmed is a pre-commercial life-sciences holding company (Lucid Diagnostics, Veris Health) whose own 10-K states outright that there is 'substantial doubt of our ability to continue as a going concern,' with the auditor issuing a matching explanatory paragraph. That is the whole thesis: this is not a valuation debate, it is a solvency one. FY2025 revenue was $71.0K — down 97.6% year-over-year and below even the $377K–$3.00M it printed in prior years — against an operating loss of $21.8M. The business consumed $5.21M of operating cash while holding just $1.54M of cash and equivalents. Current liabilities of $14.8M dwarf current assets of $2.56M. Without near-continuous outside financing this entity does not fund itself, and management concedes it has 'faced significant challenges raising capital under the current market conditions.'

The headline positives are mirages. Net income of $401K and the resulting 564.8% net margin and positive ROE are non-operating artifacts (the operating line is deeply negative on essentially no revenue), not evidence of a working business. Stockholders' equity jumping 1,461% and shares falling 62% point to balance-sheet restructuring and a reverse split / dilution regime rather than value creation — the accumulated deficit sits at -$259M. At $5.71 the market cap is $36.4M, or 513x FY2025 sales, a multiple that is meaningless because the underlying revenue base has evaporated.